Funder: National Institutes of Health

Due Dates: January 28, 2025 (New, Renewal, Resubmission, Revision) | September 28, 2026 (New, Renewal, Resubmission, Revision)

Funding Amounts: Up to $500,000 direct costs/year (UG3, 1 year) and up to $1,500,000 direct costs/year (UH3, up to 4 years); total project period not to exceed 5 years; NIH expects to fund 5–7 awards/year, $10M total/year.

Summary: Supports translational and small clinical studies to advance next-generation devices for recording and modulation in the human central nervous system, with a focus on regulatory and early clinical activities.

Key Information: Strict attachment requirements (Gantt chart, IP strategy, needs assessment, team management, long-term care plan); non-compliance leads to withdrawal. Only Significant Risk (SR) device studies requiring FDA IDE are eligible.